Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Coronavirus vaccine - Takis

Drug Profile

Coronavirus vaccine - Takis

Alternative Names: 2019-nCoV coronavirus vaccine - Takis

Latest Information Update: 11 Feb 2020

At a glance

  • Originator Takis
  • Class DNA vaccines; Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes - COVID 2019 infections

Highest Development Phases

  • Research COVID 2019 infections

Most Recent Events

  • 11 Feb 2020 Coronavirus vaccine - Takis is available for licensing as of 11 Feb 2020. http://www.takisbiotech.it/index.php/en/
  • 27 Jan 2020 Early research in COVID-2019-infections (Prevention) in Italy

Development Overview

Introduction

Coronavirus vaccine is being developed by Takis/Evvivax (a spin-off of Takis), using genetic engineering techniques, for the prevention of COVID-2019 infections. Takis and Evvivax developed vaccines based on genetic technologies capable of inducing immune responses. The technologies are based on genetic engineering techniques and on the use of viruses and DNA fragments that can be used both for gene therapy and for vaccination. Early research is underway in Italy.

The company is seeking collaboration and financing partners, for the development of COVID-2019 vaccine.

Key Development Milestones

In April 2020, Takis presented preclinical data where the coronavirus vaccine in animal models induced strong antibody response against the Covid-19 Spike protein in just 14 days [1] .

In January 2020, Takis and Evvivax initiated research on coronavirus vaccine [2] .

Drug Properties & Chemical Synopsis

  • Formulation unspecified
  • Class DNA vaccines, Viral vaccines
  • Mechanism of Action Immunostimulants
  • WHO ATC code

    J07B-X (Other viral vaccines)

  • EPhMRA code

    J7A9 (Other specified single component)

Development Status

Summary Table

Indication Qualifier Patient Segment Phase Countries Route / Formulation Developers Event Date
COVID 2019 infections - Prevention Research Italy unspecified / unspecified Takis 27 Jan 2020

Commercial Information

Involved Organisations

Organisation Involvement Countries
Takis Originator Italy
Takis Owner Italy

Licensing Availability

Licensing Organisation Available Indication Available Phase Region Date
Takis COVID 2019 infections Research - 11 Feb 2020

Development History

Event Date Update Type Comment
11 Feb 2020 Licensing Status Coronavirus vaccine - Takis is available for licensing as of 11 Feb 2020. http://www.takisbiotech.it/index.php/en/ Updated 11 Feb 2020
27 Jan 2020 Phase Change Early research in COVID-2019-infections (Prevention) in Italy [2] Updated 06 Feb 2020

References

  1. 10 April 2020 - Takis candidate vaccines against Covid-19 induces a strong antibody response.

    Media Release
  2. Takis and Evvivax developing a 2019-nCoV Coronavirus vaccine.

    Media Release
Back to top